<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain</journal-id>
<journal-id journal-id-type="publisher-id">brainj</journal-id>
<journal-title-group>
<journal-title>Brain</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-8950</issn>
<issn pub-type="epub">1460-2156</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28073790</article-id>
<article-id pub-id-type="pmc">6075536</article-id>
<article-id pub-id-type="doi">10.1093/brain/aww342</article-id>
<article-id pub-id-type="publisher-id">aww342</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Griffin</surname>
<given-names>Aliesha</given-names>
</name>
<xref ref-type="aff" rid="aww342-AFF1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hamling</surname>
<given-names>Kyla R.</given-names>
</name>
<xref ref-type="aff" rid="aww342-AFF1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Knupp</surname>
<given-names>Kelly</given-names>
</name>
<xref ref-type="aff" rid="aww342-AFF2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hong</surname>
<given-names>SoonGweon</given-names>
</name>
<xref ref-type="aff" rid="aww342-AFF3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Luke P.</given-names>
</name>
<xref ref-type="aff" rid="aww342-AFF3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baraban</surname>
<given-names>Scott C.</given-names>
</name>
<xref ref-type="aff" rid="aww342-AFF1">1</xref>
<xref ref-type="corresp" rid="aww342-COR1"></xref>
<!--<email>scott.baraban@ucsf.edu</email>-->
</contrib>
</contrib-group>
<aff id="aww342-AFF1"><label>1</label>1 Epilepsy Research Laboratory and Weill Institute for Neurosciences, Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA</aff>
<aff id="aww342-AFF2"><label>2</label>2 Department of Pediatrics, University of Colorado Denver, Denver, CO, USA</aff>
<aff id="aww342-AFF3"><label>3</label>3 Departments of Bioengineering, Electrical Engineering and Computer Science, and Biophysics Program, University of California, Berkeley, Berkeley, CA, USA</aff>
<author-notes>
<corresp id="aww342-COR1">Correspondence to: Scott C. Baraban, 840 Health Sciences East, 513 Parnassus Ave., University of California, San Francisco, San Francisco, CA, USA E-mail: <email>scott.baraban@ucsf.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date iso-8601-date="2017-01-10" pub-type="epub">
<day>10</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>140</volume>
<issue>3</issue>
<fpage>669</fpage>
<lpage>683</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri xlink:href="aww342.pdf"></self-uri>
<abstract abstract-type="teaser">
<p>Dravet syndrome is a catastrophic intractable childhood epilepsy. Using a zebrafish Dravet syndrome model, Griffin <italic>et al</italic>. reveal that serotonergic signalling is likely to mediate the antiepileptic activity of clemizole. The serotonergic drugs trazodone and lorcaserin are also antiepileptic in this model, with the latter showing promising results in patients.</p>
</abstract>
<abstract>
<title>Abstract</title>
<p>Dravet syndrome is a catastrophic childhood epilepsy with early-onset seizures, delayed language and motor development, sleep disturbances, anxiety-like behaviour, severe cognitive deficit and an increased risk of fatality. It is primarily caused by <italic>de novo</italic> mutations of the <italic>SCN1A</italic> gene encoding a neuronal voltage-activated sodium channel. Zebrafish with a mutation in the <italic>SCN1A</italic> homologue recapitulate spontaneous seizure activity and mimic the convulsive behavioural movements observed in Dravet syndrome. Here, we show that phenotypic screening of drug libraries in zebrafish <italic>scn1</italic> mutants rapidly and successfully identifies new therapeutics. We demonstrate that clemizole binds to serotonin receptors and its antiepileptic activity can be mimicked by drugs acting on serotonin signalling pathways e.g. trazodone and lorcaserin. Coincident with these zebrafish findings, we treated five medically intractable Dravet syndrome patients with a clinically-approved serotonin receptor agonist (lorcaserin, Belviq®) and observed some promising results in terms of reductions in seizure frequency and/or severity. Our findings demonstrate a rapid path from preclinical discovery in zebrafish, through target identification, to potential clinical treatments for Dravet syndrome.</p>
</abstract>
<abstract abstract-type="teaser">
<p>Dravet syndrome is a catastrophic intractable childhood epilepsy. Using a zebrafish Dravet syndrome model, Griffin <italic>et al.</italic> reveal that serotonergic signalling is likely to mediate the antiepileptic activity of clemizole. The serotonergic drugs trazodone and lorcaserin are also antiepileptic in this model, with the latter showing promising results in patients.</p>
</abstract>
<kwd-group kwd-group-type="keywords">
<kwd>epilepsy</kwd>
<kwd>zebrafish</kwd>
<kwd>drug-screening</kwd>
<kwd>serotonin</kwd>
<kwd>personalized medicine</kwd>
</kwd-group>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">NINDS</named-content>
<named-content content-type="funder-identifier">10.13039/100000065</named-content>
</funding-source>
<award-id>R01</award-id>
<award-id>NS079214</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">UCSF Catalyst Award and the Raymond &amp; Beverley Sackler Centre Sabbatical Fund</named-content>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>